Brokers Set Expectations for Pyxis Oncology FY2029 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities research analysts at Leerink Partnrs issued their FY2029 EPS estimates for Pyxis Oncology in a research note issued on Friday, May 16th. Leerink Partnrs analyst J. La. Rosa expects that the company will post earnings per share of ($0.29) for the year. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06).

Other equities research analysts have also issued reports about the company. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Monday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Pyxis Oncology Stock Down 1.6%

Shares of Pyxis Oncology stock opened at $1.21 on Monday. The company has a market cap of $74.96 million, a PE ratio of -1.17 and a beta of 1.15. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The business has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.60.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. 683 Capital Management LLC raised its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after buying an additional 135,000 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Pyxis Oncology during the 1st quarter valued at $125,000. Pier 88 Investment Partners LLC increased its position in shares of Pyxis Oncology by 296.6% during the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after purchasing an additional 292,370 shares during the last quarter. Ridgeback Capital Investments L.P. purchased a new stake in shares of Pyxis Oncology during the 4th quarter valued at $560,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Pyxis Oncology during the 4th quarter valued at $26,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.